.After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on everyone market.The Eli Lilly-partnered biotech want to note on the Nasdaq under the symbol "BIOA," according to documentations submitted along with the Securities and Substitution Commission. The provider has not publicly shared an assumed financial quantity for the offering.The clinical-stage business promotes lead prospect azelaprag, a by mouth provided small particle slated to get into period 2 screening in combo along with semaglutide-- marketed through Novo Nordisk under trademark name Wegovy for effective weight loss-- in the first fifty percent of next year. Semaglutide is also sold as Ozempic and also Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is created to integrate well along with GLP-1 medications, enhancing weight loss while protecting muscle mass. The investigational medication was actually discovered to be well-tolerated one of 265 individuals around 8 phase 1 tests, depending on to BioAge.Previously, BioAge amassed the support of Lilly to operate a test blending azelaprag along with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes as Mounjaro as well as Zepbound for fat loss. The companions are currently performing a stage 2 trial of azelaprag and also tirzepatide, along with topline end results expected in the 3rd one-fourth of 2025.The biotech is additionally considering an insulin sensitivity proof-of-concept trial examining azelaprag as a monotherapy in the initial fifty percent of next year to assist possible sign development. Moreover, the provider organizes to ask the FDA for permission in the second one-half of 2025 to launch human testing for an NLRP3 prevention targeting metabolic health conditions and also neuroinflammation.BioAge's foreseed transfer to everyone market observes a slight uptick in planned biotech IPOs from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the current IPO yard is actually a "blended photo," along with high-quality business still debuting on the public markets, just in minimized varieties, according to PitchBook.